With the uncertainty surrounding Brexit, proper monitoring and planning are essential for ensuring that your studies continue to unfold seamlessly.
In response to Brexit, we created the ACM Global Brexit Response Team (ACM-BRT) that has undergone extensive training after researching and consulting with experts regarding current and potential future customs procedures that may be implemented after the UK leaves the European Union.
The ACM-BRT worked to develop comprehensive measures to reduce the potential for any delays in sample shipments, and we are here as partners and to answer all of your questions about how the Brexit decision may impact our business and your choice about making ACM the preferred central lab to advise you on clinical trial specimen management, logistics, and reporting options.
Presently, the European Council and the United Kingdom have settled for an exit date of 31st January 2020.
While the latest deadline for the UK to leave the EU draws near, the outcome of this transition remains unsettled. At ACM Global Laboratories, our first priority is to ensure the safe and timely shipping of your clinical trial specimens. When you partner with ACM and our dedicated ACM-BRT, you will be working with a team that is continually assessing ways to reduce the risks that Brexit could have on the success of your clinical trial.
Since 2016, as Brexit developments have unfolded, the ACM-BRT has continued to closely monitor the situation and proactively keep our customers updated on all changes that take place to ensure all stakeholders have the real-time information they need.
The ACM-BRT is dedicated to ensuring that your clinical trials achieve key milestones and you keep to your submission timeline goals, meeting investor and patient expectations of delivering lifesaving therapies to market. Our subject matter experts that form the ACM-BRT are transparent and available to offer you proactive solutions regardless of the ultimate Brexit outcome.
The ACM-BRT has gone through extensive scenario planning to provide solutions on all of the outcomes that could happen with Brexit.
In the event that the UK withdraws from the EU without a deal, the ACM-BRT will deploy a logistics management strategy that includes these fundamental features, along with bespoke solutions that are tailored to your specific study and trial design:
Our experts have performed due diligence to safeguard your studies.
The ACM-BRT is fully prepared to respond to any potential Brexit outcomes in 2020 and is equipped to provide a solution to any new developments as they arise. Our mission is to continue safeguarding your studies and partner with you through our ACM-BRT, in order to keep you updated as the Brexit landscape continues to evolve.
Based on our current customers that have chosen ACM as their Central Lab of choice to manage their clinical trials in which Brexit is at play, we have identified some commonly asked questions, please refer to the frequently asked questions information (FAQ).
Please know that our company and the ACM-BRT are working to respond to changes that may arise as a result of a no-deal Brexit. Your projects are a top priority and will continue keeping you abreast of information.
We encourage you to contact us by filling out the form below with your specific questions or engage with our ACM-BRT for a no-cost evaluation and proposed solutions for how we would support your clinical trial during and after the Brexit transition period.